COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    MEN1309-01
Previous Study | Return to List | Next Study

MEN1309 Intravenous Infusion in Patients With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory Non-Hodgkin Lymphoma Phase I Study (CD205-SHUTTLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03403725
Recruitment Status : Terminated (achievement of MTD in the eligible study population)
First Posted : January 19, 2018
Last Update Posted : March 10, 2020
Information provided by (Responsible Party):
Menarini Group

Brief Summary:
The purpose of this clinical trial is to identify the highest dose of MEN1309 drug with acceptable safety profile and that can be used in patients affected by CD205-positive solid tumors and Non-Hodgkin Lymphoma

Condition or disease Intervention/treatment Phase
Metastatic Solid Tumors Relapsed/Refractory Non-Hodgkin Lymphoma Drug: MEN1309 Phase 1

Detailed Description:

This clinical trial will investigate the safety and activity of MEN1309 in patients with CD205-positive metastatic solid tumors and Non-Hodgkin Lymphoma who have tried other types of treatment for cancer without adequate response (or the cancer came back). CD205 is a protein present in certain types of cancer.

This is a Phase I study, which means that it is designed to look at several dose levels of a study drug in small groups of patients to find the dose that is well-tolerated and suitable to be administered in subsequent clinical trials in patients. The clinical trial is also looking at the effectiveness of the study drug. This is the first time the study drug will be given in humans.

The clinical trial consists of two sequential parts:

  • Part 1 involves patients with CD205-positive metastatic solid tumors and the main purpose of this part of the clinical trial is to determine the highest dose of the study drug that can be used safely in these type of cancers.
  • Part 2 involves patients with CD205-positive Non-Hodgkin Lymphoma and will test doses of MEN1309 which have demonstrated to be adequately tolerated in patients with solid tumors.

Patients participating to the clinical trial will take the study drug as intravenous infusion once every 3 weeks. The clinical trial includes four periods: a pre-screening period (to check if tumor is positive for CD205), a screening period (to check whether the participation to the clinical trial is right for patient), a treatment period (when patient receives the study drug), and a follow-up period (to check the health status of the patient after stopping study treatment).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label, Multicenter, Phase I Dose Escalation Study of MEN1309, a CD205 Antibody-Drug Conjugate,in Patients With CD205-Positive Metastatic Solid Tumors and Non-Hodgkin Lymphoma
Actual Study Start Date : August 28, 2017
Actual Primary Completion Date : October 22, 2019
Actual Study Completion Date : January 8, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: MEN1309 (Step 1-Solid Tumors)/(Step 2-NHL)

Step1: Accelerated Titration Design with 1 single pt per cohort and double dose level per cohort until grade ≥ 2 drug related toxicity. Then, study reverts to 3+3 design. Any cohort in which 1 pt experiences a DLT (along ATD or 3+3) will be expanded up to 6 pts.

Step2: MTD defined in Step 1, 3 MEN1309 dose levels will be tested (MTD-2, MTD-1, and MTD), with 6 pts per each dose level. A further MTD-3 level will be explored if 2 DLTs occur at the MTD-2 dose level.

Drug: MEN1309
MEN1309 solution for intravenous infusion once every 3 weeks

Primary Outcome Measures :
  1. Maximum-Tolerated Dose (MTD) [ Time Frame: 21-day period after the first dose ]
  2. Dose-Limiting Toxicity (DLT) [ Time Frame: 21-day period after the first dose ]

Secondary Outcome Measures :
  1. MEN1309 Pharmacokinetic (PK) parameter Cmax [ Time Frame: Day 1, 2, 3, 4, 8 and 15 of each cycle (each cycle is 21 days) ]
    Cmax is the maximum serum drug concentration

  2. MEN1309 Pharmacokinetic (PK) parameter Cmax (tmax) [ Time Frame: Day 1, 2, 3, 4, 8 and 15 of each cycle (each cycle is 21 days) ]
    time to achieve maximum serum drug concentration

  3. MEN1309 Pharmacokinetic (PK) parameter Ctrough [ Time Frame: Day 1, 2, 3, 4, 8 and 15 of each cycle (each cycle is 21 days) ]
    pre-dose serum concentration

  4. MEN1309 Pharmacokinetic (PK) parameter t1/2 [ Time Frame: Day 1, 2, 3, 4, 8 and 15 of each cycle (each cycle is 21 days) ]
    terminal serum half-life

  5. MEN1309 Pharmacokinetic (PK) parameter AUC [ Time Frame: Day 1, 2, 3, 4, 8 and 15 of each cycle (each cycle is 21 days) ]
    area under curve

  6. MEN1309 Pharmacokinetic (PK) parameter CL [ Time Frame: Day 1, 2, 3, 4, 8 and 15 of each cycle (each cycle is 21 days) ]
    systemic clearance

  7. MEN1309 Pharmacokinetic (PK) parameter Vd [ Time Frame: Day 1, 2, 3, 4, 8 and 15 of each cycle (each cycle is 21 days) ]
    volume of distribution based on the terminal phase

  8. Incidence of anti-MEN1309 antibodies [ Time Frame: Day 1 of each Cycle (each cycle is 21 days) ]
  9. Overall Survival [ Time Frame: Through study completion, an average of 3 years ]
  10. Progression free survival [ Time Frame: Through study completion, an average of 3 years ]
  11. Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Through study completion, an average of 3 years ]
    Incidence, intensity, CTCAE version 4.03 grading, seriousness and treatment-causality of TEAEs

  12. Correlation of CD205 expression in tumors with clinical activity of MEN1309 assessed according to RECIST 1.1 or Cheson Criteria (2014) in terms of Response Rate, Disease control rate, duration of response, overall survival, and progression free survival [ Time Frame: Through study completion, an average of 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  1. Male or female patients aged ≥ 18 years.
  2. Patients with:

    • confirmed diagnosis of advanced or metastatic solid tumor and diagnosis of multiple relapsed or refractory NHL;
    • progressive after last treatment received;
    • availability of archived tumor material, either as a block or slides;
    • measurable or evaluable disease by Response Evaluation Criteria in solid tumors guideline (RECIST v1.1) and by Cheson Criteria (The Lugano Classification, 2014) in NHL.
  3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2.
  4. Neutrophil count ≥ 1,500/µL; platelets ≥ 100,000/µL; haemoglobin ≥ 9 g/dL.
  5. Adequate renal and hepatic laboratory assessments.
  6. Life expectancy of at least 2 months.
  7. Woman of childbearing potential (WOCBP) who agrees to use highly effective contraception (see Appendix I).

Main Exclusion Criteria:

  1. Central nervous system involvement (excluding treated stable cerebral metastasis, not requiring therapy to control symptoms in the last 60 days).
  2. Pregnant or breastfeeding women.
  3. Life-threatening illnesses other than solid tumors and NHL, uncontrolled medical conditions or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety, or put the study outcomes at risk.
  4. Less than 2 previous cancer treatments, including high dose chemotherapy and ASCT, for NHL unless patient refuses standard therapy and/or is not eligible for ASCT.
  5. Have significant, uncontrolled, or active cardiovascular disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03403725

Layout table for location information
CHU Sart Tilman
Liège, Belgium, 4000
Centro Riferimento Oncologico
Aviano, Italy, 33081
IRCCS Ospedale San Raffaele
Milano, Italy, 20132
Vall d'Hebron Barcelona Hospital
Barcelona, Spain
START Madrid. Fundacion Jimenez Diaz
Madrid, Spain, 28040
Centro Integral Oncologico Clara Campal
Madrid, Spain, 28050
United Kingdom
NCCC Clinical Trials Pharmacy, Northern Centre for Cancer Care
Newcastle upon Tyne, United Kingdom, NE7 7DN
Sponsors and Collaborators
Menarini Group
Layout table for investigator information
Study Chair: Josep Tabernero Head, Medical Oncology Department, MD PhD Vall d'Hebron University Hospital Vall d' Hebron Institute of Oncology (VHIO) P. Vall d'Hebron 119-129 08035 Barcelona, Spain
Layout table for additonal information
Responsible Party: Menarini Group Identifier: NCT03403725    
Other Study ID Numbers: MEN1309-01
First Posted: January 19, 2018    Key Record Dates
Last Update Posted: March 10, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Menarini Group:
Solid Tumors
Non-Hodgkin Lymphoma
Antibody-Drug Coniugate
Metastatic Tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases